Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib

BACKGROUND: Osimertinib is the standard first‐line treatment for non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. Resistance to osimertinib remains a clinical challenge. However, the optimal therapy for these patients is still controversial. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Yaping, Xiong, Qi, Song, Qi, Li, Yao, Li, Xiaoyan, Qin, Boyu, Huang, Ziwei, Hu, Yi, Yang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807266/
https://www.ncbi.nlm.nih.gov/pubmed/34958168
http://dx.doi.org/10.1111/1759-7714.14271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807266/
https://www.ncbi.nlm.nih.gov/pubmed/34958168
http://dx.doi.org/10.1111/1759-7714.14271

Ejemplares similares